Amarantus Bioscience Holdings Inc (AMBS)

[JPetroInc]

Interesting they filed not one, but two delay extensions on closing the ESS deal. These were not cheap costs added to the overall purchase price - costing AMBS shareholders $300,000 and $400,000 total, with an aprox. $3.5-Mil. payment due on 1/31. Unfortunately the only way to raise that capital is with more diluted shares. Hopefully asset projections have valued ESS as an exceptional buy for the therapeutics division, even though it was not a precise fit with their known neurologic platform. I'd also like to know who made what on finders fees, if any.

All in all, AMBS continues to remain a long term play until such time as the leverage their asset base with sustainable revenue, asset sales or asset equity stakeholders. All other talk of "buy all you can under $0.08" is more tacky CEO hype and a continuous questionable strategy to sell cheap shares to the unsuspecting public.